Table 1.

The study population basic characteristics. Abbreviations: NSAIDs: nonsteroidal anti-inflammatory drugs.

Parameter	Value
Sex Female Male	15 (55.6%) 12 (44.4%)
Age (mean ± standard deviation; median)	54.44 ± 19.20; 55
Pre-vaccine autoimmune/rheumatic history None Rheumatoid Arthritis Behçet’s disease Systemic lupus erythematosus (SLE)/SLE-like Pericarditis Others	6 (22.2%) 6 (22.2%) 4 (14.8%) 3 (11.1%) 2 (7.4%) 6 (22.2%)
Vaccine BNT-162b2 mRNA-1273 ChAdOx1	23 (85.2%) 2 (7.4%) 2 (7.4%)
2nd Vaccine Administered Not administered yet	12 (44.4%) 15 (55.6%)
Days from vaccine to flare/new-onset After 1st dose After 2nd dose	21/27 (77.8%); median 4 days [1–25 days] 8/12 (66.7%); median 4 days [1–7 days]
Flare New-onset	17 (63.0%) 10 (37.0%)
Severity Mild Moderate Severe	6 (22.2%) 14 (51.9%) 7 (25.9%)
Therapy Glucocorticoids Colchicine NSAIDs Plasma exchange Hydroxychloroquine Rituximab Local steroids Pyridostigmine Combination of drugs No additional treatment	21 (77.8%) 4 (14.8%) 3 (11.1%) 2 (7.4%) 1 (3.7%) 1 (3.7%) 1 (3.7%) 1 (3.7%) 7 (25.9%) 1 (3.7%)
Response Rapid response Spontaneous resolution Slow response Intubation	21 (77.8%) 2 (7.4%) 2 (7.4%) 1 (3.7%)